Pablo Menéndez Buján
Jefe de Grupo
Research group
Dr. Pablo Menéndez Buján obtained his BSc in Biochemistry and his PhD in Medicine (Hematology and Bone Marrow Transplantation) from the University of Salamanca in 1997 and 2002, respectively, under the supervision of Prof. Alberto Orfao and Prof. Jesús San Miguel. He subsequently completed postdoctoral training in stem cell biology at the Robarts Research Institute in London, Canada (2002-2005), and in childhood leukemia research under Sir Prof. Mel Greaves at the Institute of Cancer Research in London, UK (2005-2007).
After returning to Spain as a Principal Investigator at GENyO in Granada (2007-2013), he was appointed ICREA Research Professor at the Josep Carreras Leukemia Research Institute (IJC) in 2013, where he leads the Developmental Cancer, Immunotherapy, and Stem Cell Biology group. Since 2015, he is also Associate Professor at the School of Medicine of the University of Barcelona.
Dr. Menéndez has published 251 peer-reviewed publications (H-index 69; over 17,100 citations) and has secured highly competitive funding, including an ERC Consolidator Grant and ERC Proof-of-Concept Grants. He holds 12 patents, 6 of which have been licensed to Health Canada and to OneChain Immunotherapeutics (OCI), a clinical-stage CAR T-cell spin-off he founded in 2020 that has raised €20 million in combined equity and non-dilutive funding. His CD1a-CAR T-cell therapy for T-cell leukemia and lymphoma - awarded both EMA and FDA orphan drug designations - is currently in a Phase I clinical trial.
pmenendez@carrerasresearch.org
Last Publications
- Ahlgren, L, Pilheden, M, Sturesson, H, Song, GC, Walsh, MP, Yang, MJ, Maillard, M, Zhao, HB, Cheng, ZS, Singh, V, Castor, A, Pronk, CJ, Marquart, HV, Lausen, B, Schneider, P, Barbany, G, Tamm, KP, Abrahamsson, J, Lohi, O, Fogelstrand, L, Menendez, P, Pieters, R, Zhang, JH, Lindkvist-Petersson, K, Yang, JJ, Gruber, TA, Stam, RW, Ma, J and Hagström-Andersson, AK The genomic landscape of relapsed infant and childhood KMT2A-rearranged acute leukemia Nature Communications . 16(1): .
- Palma, LG, Kartha, GM, Maqueda, M, Barrero, M, Canton, E, Iglesias, A, González, J, Herrero-Molinero, P, Torres-Ruiz, R, Payer, B, Bueno, C, Menéndez, P, Espinosa, L and Bigas, A An unbiased genomewide screen uncovers 7 genes that drive hematopoietic stem cell fate from mouse embryonic stem cells BLOOD . 146(3): 328-340.
- Almaghrabi, R, Alyahyawi, Y, Keane, P, Mian, SA, Habel, K, Atkinson, A, Ward, C, Bayley, R, Sargas, C, Menendez, P, Murphy, GJ, Sobahy, T, Baghdadi, MA, Flemban, AF, Kabrah, SM, Torres-Ruiz, R, Papapetrou, EP, Akerman, I, Raghavan, M, Barragan, E, Bonnet, D, Bonifer, C and Garcia, P A heterozygous CEBPA mutation disrupting the bZIP domain in a RUNX1 and SRSF2 mutational background causes MDS disease progression Nature Communications . 16(1): .
